Hanmi Science Co

Hanmi Science Co Liabilities

The The Liabilities of Hanmi Science Co (008930.KS) as of Oct 10, 2026 is 529.85 B KRW. In the previous year, The Liabilities was 510.38 B KRW — a change of 3.82% (higher).

Liabilities

529.85 BKRW

YoY

3.82%

Last updated:

In 2025, Hanmi Science Co's total liabilities amounted to 529.85 B KRW, a 3.82% difference from the 510.38 B KRW total liabilities in the previous year.

The Hanmi Science Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
263.45 B KRW
Jan 1, 2019
265.15 B KRW
Jan 1, 2020
264.49 B KRW
Jan 1, 2021
259.60 B KRW
Jan 1, 2022
384.94 B KRW
Jan 1, 2023
438.70 B KRW
Jan 1, 2024
510.38 B KRW
Jan 1, 2025
529.85 B KRW
The Hanmi Science Co Liabilities history
YEARLiabilitiesYoY
529.85 BKRW+3.82%
510.38 BKRW+16.34%
438.70 BKRW+13.96%
384.94 BKRW+48.28%
259.60 BKRW-1.85%
264.49 BKRW-0.25%
265.15 BKRW+0.64%
263.45 BKRW-3.72%
273.63 BKRW-14.94%
321.68 BKRW-7.50%
347.77 BKRW+6.98%
325.08 BKRW—
Access this data via the Eulerpool API

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Hanmi Science Co's Liabilities

Hanmi Science Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hanmi Science Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hanmi Science Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hanmi Science Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hanmi Science Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hanmi Science Co stock

The Liabilities of Hanmi Science Co is 529.85 B KRW in 2025.

The Liabilities of Hanmi Science Co changed from 510.38 B KRW to 529.85 B KRW, representing a 3.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Hanmi Science Co historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Hanmi Science Co

All Key Metrics — Hanmi Science Co